new clinical parameters for determining a haematological toxicity in a strahlenimmuntherapie

摘要

New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.